Skip to main content
Terug
Watch Compare

Prelude Therapeutics Inc

Datakwaliteit: 100%
PRLD
NASDAQ Manufacturing Chemicals
€ 4,08
▼ € 0,32 (-7,27%)
Marktkapitalisatie: 274,72 M
Prijs
€ 4,37
Marktkapitalisatie
274,72 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -56,37 M
Capital efficient — spends only 0,55% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)73,43%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-148,09%
Onder sectorgemiddelde (-54,47%)
ROIC-96,86%
Net Margin-819,59%
Op. Margin-861,33%

Veiligheid

Debt / Equity
N/A
Current Ratio3,21
Interest CoverageN/A

Waardering

PE (TTM)
-2,76
Onder sectorgemiddelde (-1,49)
P/B Ratio4,69
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -2,8 -1,5
P/B 4,7 1,6
ROE % -148,1 -54,5
Net Margin % -819,6 -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 4,08
+26.6%
Koersdoel
€ 5,17
€ 4,50
€ 5,00
€ 6,00
Vooruitzicht
Forward WPA -€ 0,44
Omzet Sch. 100,00 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 0,44
-€ 0,44 – -€ 0,44
 100,00 M 1
FY2026 -€ 1,11
-€ 1,11 – -€ 1,11
 33,33 M 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,18 -€ 0,20 -11,1%
Q32025 -€ 0,36 -€ 0,26 +26,8%
Q22025 -€ 0,43 -€ 0,41 +5,0%
Q12025 -€ 0,47 -€ 0,42 +9,7%

ETFs Holding This Stock

CNCR CNCR
0,51% weight
BRSIX BRSIX
0,07% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 73,43% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 12,14 M Net Income (TTM) -99,50 M
ROE -148,09% ROA -94,91%
Gross Margin N/A Operating Margin -861,33%
Net Margin -819,59% Free Cash Flow (TTM) -56,37 M
ROIC -96,86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 3,21
Interest Coverage N/A Asset Turnover 0,12
Working Capital 40,14 M Tangible Book Value 58,53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,76 Forward P/E N/A
P/B Ratio 4,69 P/S Ratio 22,63
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2,75 Fwd Earnings Yield N/A
FCF Yield -20,52%
Market Cap 274,72 M Enterprise Value 227,19 M
Per Share
EPS (Diluted TTM) -1,29 Revenue / Share 0,19
FCF / Share -0,90 OCF / Share -0,90
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,55% FCF Conversion 56,65%
SBC-Adj. FCF -71,99 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 12,14 M 7,00 M — — —
Net Income -99,50 M -127,17 M -121,83 M -115,44 M -111,69 M
EPS (Diluted) -1,29 -1,68 -2,02 -2,44 —
Gross Profit — — — — —
Operating Income -104,57 M -139,71 M -132,28 M -123,54 M -113,74 M
EBITDA — — — — —
R&D Expenses 94,30 M 118,00 M 103,39 M 92,89 M 86,78 M
SG&A Expenses — — — — —
D&A 1,71 M 1,77 M 1,17 M 1,32 M 915.000,0
Interest Expense — — — — —
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 141,32 M 175,52 M 277,67 M 220,50 M 305,10 M
Total Liabilities 72,68 M 44,06 M 40,58 M 25,06 M 19,20 M
Shareholders' Equity 68,64 M 131,46 M 237,09 M 195,44 M 285,90 M
Total Debt — — — — —
Cash & Equivalents 35,26 M 12,47 M 25,29 M 30,61 M 31,83 M
Current Assets 105,69 M 135,90 M 235,59 M 204,38 M 295,12 M
Current Liabilities 52,99 M 25,64 M 21,83 M 21,70 M 19,20 M